
-
Actinium Pharmaceuticals, Inc. NYSE American:ATNM Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
Location: 100 Park Avenue, New York, NY, 10017, United States | Website: https://www.actiniumpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-15.85M
Cash
65.33M
Avg Qtr Burn
-8.318M
Short % of Float
5.89%
Insider Ownership
1.79%
Institutional Own.
30.02%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Iomab-B (CD45) (apamistamab-I-131) Details Hematopoietic cell transplantation , Acute myeloid leukemia | Phase 2/3 Initiation | |
Iomab-ACT (CAR-T – CD45) Details Lymphoma, Diffuse large B cell lymphoma | Phase 1/2 Data readout | |
Actimab-A + venetoclax Details Relapsed/refractory acute myeloid leukemia | Phase 1/2 Update | |
Actimab-A + venetoclax + ASTX-727 Details Acute myeloid leukemia | Phase 1 Data readout | |
Actimab-A + CLAG-M Details Relapsed/refractory acute myeloid leukemia | Phase 1 Update | |
Iomab-ACT (CAR-T – CD45) Details Sickle cell disease, Blood disorder | Phase 1 Initiation | |
Iomab-ACT (GeneTx – CD45) Details Lymphoma, Acute radiation syndrome | Failed Discontinued | |
Actimab-A + venetoclax Details Myelodysplastic syndrome | Failed Discontinued |